Affordable Access

Publisher Website

Integrated in vivo pharmacology using an instrumented, unrestrained and conscious rat platform: Application to rat models of diabetes

Journal of Pharmacological and Toxicological Methods
Publication Date
DOI: 10.1016/j.vascn.2005.09.005
  • Blood
  • Blood Pressure
  • Catheter
  • Diabetes
  • Instrumentation
  • Method
  • Lipids
  • Metabolism
  • Rat
  • Surgery
  • Biology
  • Chemistry
  • Medicine
  • Pharmacology


Abstract Introduction We define the technical and methodological aspects that led to a practical and reproducible biological in vivo platform allowing the measurement of more than 65 physiobiochemical parameters on a daily basis in freely moving conscious animals. Such a platform presents the ability to unleash incremental information in the hands of modern-day pharmacologists and physiologists. Methods To validate this platform, we fully characterized three rat models of Type 1 and Type 2 diabetes and their respective controls. Control, streptozotocin- and alloxan-diabetic Wistar rats in addition to ZDF- Lean and ZDF- Fatty rats were chronically implanted with an arterial catheter and kept in metabolic cages. The catheter was connected to a minipump infusing saline at a constant rate to maintain patency and used to collect blood and measure hemodynamic parameters on a daily basis. Results Catheter implantation was successful in over 95% of animals and catheter patency was successfully maintained for 30 days in about 75% of animals. The three diabetic rat strains showed elevations in food and water consumption, urinary output, plasma glucose, blood urea nitrogen, triglycerides and cholesterol. The two Type I models also showed a depressed body weight and hemodynamic function. The STZ model differed from the alloxan-model by elevations in liver enzyme activities (AST, ALT, and bilirubin) and a more severe dyslipidemia (triglycerides and total cholesterol). The ZDF- Fatty rats distinguished themselves by higher body weight and elevated white blood cell counts. Discussion This integrated platform represents a significant improvement in standard in vivo evaluations and could greatly improve the pace of development of potential new drugs.

There are no comments yet on this publication. Be the first to share your thoughts.